Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.
She has a BA in English language and literature from Rutgers University. You can connect with Julia on LinkedIn.
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment
Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.
New FTC Lawsuit Against PBMs Has Broad Implications for Pharmaceuticals, Ted Okon Says
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit managers (PBMs) could affect the future of pharmaceuticals and oncology.
OS Disparity, Driver Gene Variations by Race and Ethnicity Seen in CRC
A substantial overall survival (OS) disparity by race and ethnicity was found in patients with colorectal cancer (CRC), with socioeconomic status and tumor molecular features largely contributing to the difference in OS.
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.